Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?

Lung Cancer. 2024 May:191:107561. doi: 10.1016/j.lungcan.2024.107561. Epub 2024 Apr 4.

Authors

Tadashi Nishimura¹, Hajime Fujimoto²

Affiliations

¹ Department of Pulmonary Medicine, Mie Chuo Medical Center, 2158-5 Hisaimyojin-Cho, Tsu City, Mie 514- 1101, Japan. Electronic address: shidatafireflash@gmail.com.
² Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

PMID: 38582025
DOI: 10.1016/j.lungcan.2024.107561

No abstract available

Publication types

Letter

MeSH terms

Humans
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms* / immunology
Prognosis

Substances

Immune Checkpoint Inhibitors